CG Oncology, Inc. Common stock (CGON)vsRevolution Medicines Inc (RVMD)
CGON
CG Oncology, Inc. Common stock
$72.35
+0.49%
HEALTHCARE · Cap: $6.38B
RVMD
Revolution Medicines Inc
$203.77
+0.21%
HEALTHCARE · Cap: $44.44B
Smart Verdict
WallStSmart Research — data-driven comparison
CG Oncology, Inc. Common stock generates 739% more annual revenue ($6.23M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. CGON earns a higher WallStSmart Score of 32/100 (F).
CGON
Avoid32
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 1983.0% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
0.0% margin — thin
Weak financial health signals
ROE of -17.1% — below average capital efficiency
Trading at 16.8x book value
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : CGON
The strongest argument for CGON centers on Revenue Growth, Debt/Equity, Altman Z-Score. Revenue growth of 1983.0% demonstrates continued momentum.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : CGON
The primary concerns for CGON are EPS Growth, Profit Margin, Piotroski F-Score.
Bear Case : RVMD
The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.
Key Dynamics to Monitor
CGON profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.
RVMD carries more volatility with a beta of 1.41 — expect wider price swings.
CGON is growing revenue faster at 1983.0% — sustainability is the question.
CGON generates stronger free cash flow (-47M), providing more financial flexibility.
Bottom Line
CGON scores higher overall (32/100 vs 24/100) and 1983.0% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CG Oncology, Inc. Common stock
HEALTHCARE · BIOTECHNOLOGY · USA
CG Oncology, Inc. is a clinical-stage biotechnology firm focused on developing groundbreaking cancer therapies, particularly through its lead product, CG0070, an oncolytic virus therapy designed for non-muscle invasive bladder cancer. The company is well-positioned to meet significant unmet medical needs in oncology, emphasizing the potential to improve patient outcomes and transform treatment approaches. With a robust proprietary technology platform and a commitment to advancing clinical trials and securing regulatory approvals, CG Oncology represents a compelling investment opportunity for institutional investors interested in pioneering advancements in cancer care.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?